A detailed history of Simplex Trading, LLC transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Simplex Trading, LLC holds 55,099 shares of MREO stock, worth $134,992. This represents 0.01% of its overall portfolio holdings.

Number of Shares
55,099
Previous 33,855 62.75%
Holding current value
$134,992
Previous $139,000 38.13%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025

BUY
$3.29 - $4.62 $69,892 - $98,147
21,244 Added 62.75%
55,099 $192,000
Q3 2024

Nov 08, 2024

SELL
$3.45 - $4.87 $26,006 - $36,710
-7,538 Reduced 18.21%
33,855 $139,000
Q2 2024

Jul 25, 2024

BUY
$2.58 - $4.25 $31,349 - $51,641
12,151 Added 41.55%
41,393 $149,000
Q1 2024

Apr 25, 2024

BUY
$2.3 - $4.05 $67,256 - $118,430
29,242 New
29,242 $96,000
Q4 2022

Feb 02, 2023

BUY
$0.5 - $1.01 $2,164 - $4,371
4,328 Added 232.44%
6,190 $4,000
Q3 2022

Nov 04, 2022

SELL
$0.82 - $1.73 $56,681 - $119,584
-69,124 Reduced 97.38%
1,862 $1,000
Q2 2022

Aug 03, 2022

BUY
$0.33 - $1.69 $23,092 - $118,261
69,977 Added 6935.28%
70,986 $79,000
Q1 2022

May 02, 2022

SELL
$1.04 - $1.7 $114,476 - $187,125
-110,074 Reduced 99.09%
1,009 $1,000
Q4 2021

Feb 23, 2022

BUY
$1.51 - $2.59 $150,501 - $258,145
99,670 Added 873.3%
111,083 $177,000
Q3 2021

Oct 28, 2021

SELL
$2.2 - $3.17 $11,268 - $16,236
-5,122 Reduced 30.98%
11,413 $35,000
Q2 2021

Aug 12, 2021

BUY
$2.94 - $4.08 $26,918 - $37,356
9,156 Added 124.08%
16,535 $52,000
Q1 2021

Apr 26, 2021

BUY
$2.6 - $4.43 $19,185 - $32,688
7,379 New
7,379 $24,000

Others Institutions Holding MREO

About Mereo Biopharma Group plc


  • Ticker MREO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,986,000
  • Market Cap $306M
  • Description
  • Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...
More about MREO
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.